Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Vir Biotechnology, Bank of America Securities

Digest more
Top News
Overview
Highlights
 · 1d
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities ...

Continue reading

 · 1d
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
TMCnet · 12h
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
 · 13h
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today a...

Continue reading

TMCnet · 13h
IQVIA CFO to Speak at Bank of America Health Care Conference 2026
 · 13h
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
 · 21h
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
Rhythm’s lead asset, IMCIVREE ® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body weig...

Continue reading

 · 22h
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
TMCnet · 22h
Zimmer Biomet to Present at the BofA Securities 2026 Health Care Conference
1d

Understanding Biotechnology: From Healthcare to Investment Opportunities

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and how to wisely invest in this innovative field.
4y

7 Best Biotech ETFs to Buy Now

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual firms.
1d

Andrew Hillman Grant Opens 2026 Biotech Application Cycle in Dallas

Andrew Hillman Grant for Biotech Introduces National Opportunity for Undergraduate Talent to Explore the Future of
1d

Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at
Frontiers
8d

Next-Generation Fermentation: Bridging Food Biotechnology and Gastronomy

Fermentation has evolved from a traditional preservation method into a cornerstone of modern food innovation, where the intersection of bioprocess
PharmaTimes
7d

BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development

BioDuro has entered a strategic partnership with CTI Biotechnology to build an integrated preclinical development platform spanning drug discovery through to investigational new drug submission.
Morningstar
2mon

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer – Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a ...
2y

7 Best Biotech Stocks to Buy for 2025

The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech industry is alive and well. Here are seven top biotech stocks with "overweight" ratings from Morgan Stanley analysts:
STAT
1mon

‘Takeover Tuesday’ saves biotech’s quarter

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s ...
2don MSN

Immune System Biotech Odyssey Seeks $238.3 Million in US IPO

Odyssey Therapeutics Inc., a clinical stage biotechnology firm focused on autoimmune and inflammatory diseases, is seeking to raise $238.3 million in an initial public offering.
  • Privacy
  • Terms